You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動丨維昇藥業漲近7%,連續第二日上漲
格隆匯 04-23 10:30
延續近日漲勢,生物科技股今日再度走強,其中,被稱爲港股“生長髮育第一股”的維昇藥業-B(2561.HK)盤中漲近7%報47.3港元,爲連續第二日上漲。維昇藥業於2018年成立,是一家專注於內分泌治療領域的創新型生物醫藥公司。核心產品管線均聚焦內分泌領域,深耕生長髮育疾病,其中核心產品隆培促生長素是第一款同時獲得FDA及EMA批準用於治療兒童生長激素缺乏症(PGHD)的長效生長激素(LAGH),也是唯一一款經臨牀試驗證實效果優於生長激素日製劑的長效生長激素。目前,隆培促生長素已經完成中國3期關鍵性試驗,國內上市申請已獲受理,預計將於今年內獲批。這也是維昇藥業目前產品商業化上市中進程最快的。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account